company background image
OCGN

Ocugen NasdaqCM:OCGN Stock Report

Last Price

US$2.86

Market Cap

US$619.4m

7D

10.9%

1Y

-63.6%

Updated

07 Aug, 2022

Data

Company Financials +
OCGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OCGN Stock Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.

Ocugen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ocugen
Historical stock prices
Current Share PriceUS$2.86
52 Week HighUS$17.65
52 Week LowUS$1.67
Beta4.21
1 Month Change-7.74%
3 Month Change43.00%
1 Year Change-63.61%
3 Year Changen/a
5 Year Changen/a
Change since IPO0.35%

Recent News & Updates

Aug 04

Ocugen Q2 2022 Earnings Preview

Ocugen (NASDAQ:OCGN) is scheduled to announce Q2 earnings results on Friday, August 5th, before market open. The consensus EPS Estimate is -$0.08 (+38.5% Y/Y) Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Jul 18

Ocugen: A First Take

Today, we take our first look at a small-cap biotech firm called Ocugen. The company has several early-stage gene therapies and is also trying to become a late entrant into the Covid19 vaccine market. An investment analysis follows in the paragraphs below. The best revenge is to be unlike him who performed the injury." - Marcus Aurelius, Meditations Today, we put Ocugen (OCGN) in the spotlight for the first time. The company has several early stage candidates in development. It is also seeking to enter the Covid-19 vaccine market with a license from a large drug concern in India. An analysis follows in the paragraphs below. Seeking Alpha Company Overview: Ocugen is a clinical-stage biopharmaceutical company. The firm is focused on the developing gene therapies to cure blindness diseases. The company also has the license from Bharat Biotech to sell Indian COVAXIN vaccine in the US, Canada and Mexico, pending approval in those countries. Under this agreement, Ocugen would garner 45% of all profits of sales in these countries. Bharat has secured an Emergency Use Listing from the World Health Organization or WHO and the vaccine provided results against the Delta variant of the coronavirus. In January, the company posted results that showed a booster dose of COVAXIN was effective against both the Delta and Omicron variants of Covid-19. In June, COVAXIN showed higher efficacy and superior response in children than what was seen in adults. In March, the FDA declined to issue an Emergency Use Authorization for the use of COVAXIN in those aged 2 to 18 years old in the U.S. April Company Presentation Outside COVAXIN commercialization, Ocugen is focused on inherited retinal diseases for which there are no options and only one gene therapy modality exists. According to their website: Ocugen's modifier gene therapy, unlike traditional gene therapy, as shown in preclinical models to effect the regulators of genes called nuclear hormone receptors, or NHRs. Activating these NHRs modulates gene activity and maintains homeostasis. When gene networks are not functioning properly, this unbalanced state can lead to disease." April Company Presentation Currently, the stock trades just above $2.50 a share and sports an approximate $550 million market capitalization. April Company Presentation Recent Developments: The company got some good news in late May when the FDA lifted the clinical hold on its Phase 2/3 clinical trial for COVID-19 shot, COVAXIN. This study involves 400 individuals in the study, 18 years or older. In Canada, Ocugen is dealing with the governments' objections to its rolling submission there which involve numerous 'deficiencies'. The company has provided responses to these requests, but there is no current timetable for resolution. Complicating things further, in early April, the WHO suspended COVAXIN from supplying United Nations agencies. Bharat has suspended the production of COVAXIN for export while it addresses WHO concerns about issues around its manufacturing facility producing these vaccines. Again, there is no firm timetable for resolution to this challenge. COVAXIN does has Emergency Use Authorization in Mexico for adults and application for pediatric use, and the 2 to 18 year old age group is under review. Ocugen is in the process of commercialization in the country. Obviously, this effort is dependent on Bharat getting its manufacturing issues corrected and being able to export COVAXIN again. April Company Presentation The company also has a couple of other focus areas that are in the early stages of development. The most advanced of these is a candidate called OCU400. The FDA has approved an IND for this therapy targeting Retinitis Pigmentosa. Currently, OCU400 is in ongoing Phase 1/2 safety and efficacy clinical trial. In May, the company dosed the second of 18 patients in this study, consisting of three cohorts of three different doses. If this trial is successful, the company will initiate a Phase 3 clinical trial which could then see a marketing application if results are positive. Approximately two million people globally struggle with this disease and there are no approved therapies to stop disease progression currently.

Jul 05

Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant

With the U.S. FDA saying that COVID-19 booster vaccines need to include protection against Omicron variant subvariants, Ocugen (NASDAQ:OCGN) could see its fortunes improved. In January, Ocugen and partner Bharat Biotech reported data on a booster dose of its Covaxin vaccine that showed it neutralized both the Omicron and Delta variants. Covaxin is authorized in 14 countries and by the World Health Organization, but the U.S. is not one of them. The U.S. FDA put a clinical hold on a phase 2/3 trial of the shot in April, but removed it in May. One of the key benefits of Covaxin is that unlike mRNA vaccines, it does not require freezing cold storage. However, given that Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX) are all developing Omicron-targeted vaccines, even if Covaxin is authorized, it would face stiff competition. In June, interim data from the phase 2/3 trial found that the efficacy of Covaxin was better in children than in adults.

Shareholder Returns

OCGNUS BiotechsUS Market
7D10.9%5.7%1.0%
1Y-63.6%-24.5%-12.9%

Return vs Industry: OCGN underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: OCGN underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is OCGN's price volatile compared to industry and market?
OCGN volatility
OCGN Average Weekly Movement14.5%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: OCGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: OCGN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a56Shankar Musunurihttps://www.ocugen.com

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market.

Ocugen Fundamentals Summary

How do Ocugen's earnings and revenue compare to its market cap?
OCGN fundamental statistics
Market CapUS$619.38m
Earnings (TTM)-US$62.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCGN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$62.83m
Earnings-US$62.83m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio1.5%

How did OCGN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OCGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OCGN?

Other financial metrics that can be useful for relative valuation.

OCGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-8.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does OCGN's PB Ratio compare to its peers?

OCGN PB Ratio vs Peers
The above table shows the PB ratio for OCGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.4x
CCCC C4 Therapeutics
1.8x-20.8%US$624.6m
TSVT 2seventy bio
1.4x10.9%US$624.9m
AVTE Aerovate Therapeutics
3.8x-20.5%US$610.3m
KZR Kezar Life Sciences
2.7x-5.5%US$626.5m
OCGN Ocugen
5.4x76.1%US$619.4m

Price-To-Book vs Peers: OCGN is expensive based on its Price-To-Book Ratio (5.4x) compared to the peer average (2.4x).


Price to Earnings Ratio vs Industry

How does OCGN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: OCGN is expensive based on its Price-To-Book Ratio (5.4x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is OCGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OCGN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OCGN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of OCGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OCGN ($2.86) is trading below our estimate of fair value ($17.46)

Significantly Below Fair Value: OCGN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Ocugen forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


76.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: OCGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OCGN is expected to become profitable in the next 3 years.

Revenue vs Market: OCGN's revenue (64.8% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: OCGN's revenue (64.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OCGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Ocugen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-39.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OCGN is currently unprofitable.

Growing Profit Margin: OCGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OCGN is unprofitable, and losses have increased over the past 5 years at a rate of 39.6% per year.

Accelerating Growth: Unable to compare OCGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).


Return on Equity

High ROE: OCGN has a negative Return on Equity (-55.06%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Ocugen's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OCGN's short term assets ($122.6M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: OCGN's short term assets ($122.6M) exceed its long term liabilities ($5.6M).


Debt to Equity History and Analysis

Debt Level: OCGN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if OCGN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OCGN has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 49.1% each year.


Discover healthy companies

Dividend

What is Ocugen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OCGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCGN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OCGN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Shankar Musunuri (58 yo)

2.92yrs

Tenure

US$8,141,351

Compensation

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. Dr. Musunuri has served as the Co-Founder, C...


CEO Compensation Analysis

Compensation vs Market: Shankar's total compensation ($USD8.14M) is above average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Shankar's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OCGN's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: OCGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.


Top Shareholders

Company Information

Ocugen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ocugen, Inc.
  • Ticker: OCGN
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$619.379m
  • Shares outstanding: 216.57m
  • Website: https://www.ocugen.com

Number of Employees


Location

  • Ocugen, Inc.
  • 263 Great Valley Parkway
  • Suite 160
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.